NAVENTUS LIFE SCIENCES SUMMIT

F.R. Martelet, M.D., CEO

29th September 2021

1

Forward-looking statement

IMPORTANT NOTICE

The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require preparation of further prospectuses or other offer documentation, or be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

No representation or warranty expressed or implied is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinion contained herein.

The information in this presentation may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

FORWARD LOOKING STATEMENTS

This presentation contains forward-looking statements that reflect management's current views with respect to certain future events and potential

financial performance. Although Oasmia believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of various factors.

Important factors that may cause such a difference for Oasmia include but are not limited to: (i) the macroeconomic development, (ii) change in the competitive climate and (iii) change in interest rate level.

This presentation does not imply that Oasmia has undertaken to revise these forward-looking statements, beyond what is required by applicable law or applicable stock exchange regulations if and when circumstances arise that will lead to changes compared to the date when these statements were provided.

2

Building a sustainable global oncology business

Approved product & growing pipeline

Portfolio expansion strategy

focused on hard-to-treatand late-

targeting multiple oncology

stage cancers with limited treatment

MoAs through in-licensing &

options

M&A

Strong in-house capabilities including

New leadership team,

regulatory, development &

strategy & focus since

global partnering relationships

March 2020

3

Our areas of focus

Oncology R&D: in-licensed & wholly-owneddevelopment-stage assets:

  • Cantrixil

• Docetaxel Micellar

  • Strategic pipeline development

Commercial: revenues from out-licensed products and technologies:

  • Apealea®

• XR-17™/XR-18 /XR-19

  • Animal health assets (for partnering)

4

Oncology R&D: emerging portfolio ready for further expansion

Registration /

Commercial

Product

Indication

Pre-clinical

Phase 1

Phase 2

Phase 3

approval

Launch

Geography

Human Health Portfolio

Cantrixil

Ovarian cancer

Global

Docetaxel

Prostate cancer

EU/EAA

micellar

Animal Health Portfolio (Canines)

Paccal vet

Mammary

USA

(paclitaxel)

Carcinoma

Doxophos vet

Lymphoma

USA

(doxorubicin)

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Oasmia Pharmaceutical AB published this content on 29 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 October 2021 07:41:04 UTC.